AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 56 min read$KRMD

KORU Medical Systems, Inc. (KRMD): Results of Operations and Financial Condition

KORU Medical Systems, Inc. (KRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 ex_99-1.htm PRESS RELEASE, DATED AUGUST 5, 2026 EXHIBIT 99.1 KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance MAHWAH, NJ – August 5, 2026 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading

Original reporting
SEC EDGAR 8-K
Published Aug 5, 2026, 8:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$KRMD
Bullish
high confidence
Mentioned
$KRMD
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$KRMDBullishMed
01

Why it matters

Traders can update valuation and positioning based on the narrowed revenue and gross margin targets, improved gross margin and net income, and management’s stated strategic shift in U.S. oncology regulatory approach.

02

Market read

The filing provides fresh, quantitative guidance and profitability updates that can drive near-term repricing and trading decisions.

03

What to watch

Pharma services and clinical trials revenue fell 35% YoY, and international growth is expected to moderate due to European launch conversion timing, which could cap upside if execution slips.

Relevance 7/10Novelty 8/10Timing: after-hours/filing today, guidance update for FY 2026

Background

This is an SEC 8-K with the company’s Q2 2026 financial results and an updated full-year 2026 guidance range.

Company-level read

Ticker impact

$KRMDBullishHigh confidence
Context

KORU Medical reported Q2 2026 results and narrowed FY 2026 guidance, including revenue $47.5-$48.5M and gross margin 62%-64%.

Expected impact

Moderate positive bias for the next few sessions as traders price in the updated FY revenue and margin outlook.

Evidence & confidence

The filing is a primary-source earnings and guidance update with specific quantitative targets and profitability improvements, which typically drives immediate repricing for small/mid-cap biotech/medtech names.

Market effects

Sector

Signals demand strength in subcutaneous infusion and SCIg-related volumes, potentially supportive for peers focused on large-volume subcutaneous delivery.

Regional

International core revenue growth (up 59.1% YoY) highlights Europe conversion dynamics as a key driver.

Global

Limited broader macro relevance; primarily company-specific medtech execution and regulatory strategy (510(k) withdrawal).

Counterpoint

What could challenge this read

Withdrawing the U.S. 510(k) for FreedomEDGE with Phesgo could be viewed as a near-term setback to U.S. oncology growth plans despite the shift to alternative higher-volume molecules.

Key entities

  • company
    KORU Medical Systems, Inc.

    NASDAQ-listed medical technology company reporting Q2 2026 results and updating FY 2026 guidance.

  • product
    FreedomEDGE

    U.S. oncology device referenced in the company’s decision to withdraw a 510(k) application.

  • product
    Phesgo

    Referenced in the withdrawn 510(k) application tied to FreedomEDGE.

Read at source← All news

Related articles

AUG 7
$KRMDMed

KORU Medical Systems Q2 Earnings Call Highlights

KORU Medical Systems (KRMD) reported Q2 PST revenue of $0.6M, down 35% year over year, citing lower clinical-trial orders and timing. Gross margin rose to 65.1% from 63.5%. The company narrowed full-year revenue guidance to $47.5M-$48.5M, raised gross-margin guidance to 62%-64%, ended with $8.3M cash, and expects positive adjusted EBITDA. It acquired a connected monitoring technology asset and shifted some FDA oncology timing.

yahoo.com7 min
AUG 7
$KRMDMedAI 8/10

KORU Medical Systems, Inc. Q2 2026 Earnings Call Summary

KORU Medical Systems reported Q2 2026 revenue up 18% and first positive net income since 2019, with domestic revenue up 12% and international revenue up 59%. It withdrew a US FDA 510(k) for Phesgo, narrowed FY revenue guidance to $47.5M-$48.5M, raised gross margin to 62%-64%, and expects positive adjusted EBITDA in 2026.

yahoo.com7 min
AUG 8
$GRDNMed

Guardian Pharmacy Services Q2 Earnings Call Highlights

Guardian Pharmacy Services (GRDN) reported Q2 net income of $22.1M vs $8.8M a year earlier, including an $8.5M payer-dispute settlement recorded as other income. The company expects H2 revenue to fall low-single digits YoY due to IRA pricing reductions, with adjusted EBITDA margin stable in Q3 and seasonally higher in Q4. It also appointed Morris as COO and named a new CFO.

yahoo.com5 min
AUG 8
$GPNMed

Global Payments Q2 Earnings Call Highlights

Global Payments (NYSE:GPN) reported Q2 results and discussed its Worldpay integration and Genius point-of-sale rollout. Management guided for about 4.5% revenue growth in 2H, margins near 43%, and cited drivers including sales-force ramp and enterprise go-lives. Q2 adjusted net revenue by segment: SMB $1.51B, Enterprise $838M, Platforms $628M. Adjusted free cash flow was $687M; net leverage just below 3.5x.

yahoo.com7 min
AUG 8
$CXWMed

Private prisons announce $1.4 billion in revenue as immigration detentions climb

CoreCivic and GEO Group reported combined $1.4 billion in quarterly revenue for April-June as U.S. immigration detention nears record levels. CoreCivic said revenue rose 27% to $684.9 million, including a $1.6 billion DHS facility sale not yet reflected. GEO Group reported $732.1 million revenue, up 15%, with growth in ICE ankle monitoring and related services.

wbaa.org4 min
AUG 8
$CATMedAI 8/10

Critical Minerals: How Data Centres are Boosting Caterpillar

Caterpillar shares rose about 12% on 4 August after its Q2 results beat analyst expectations. The company reported revenue of $20.54bn, up 24% year on year, and adjusted EPS of $8.17 versus $6.20 expected. Operating profit was $4.3bn. Order backlog reached $72.1bn, up 92%, supporting construction and power demand tied to data centres.

miningdigital.com6 min
KORU Medical Systems, Inc. (KRMD): Results of Operations and Financial Condition — alphai